Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.08
DGX's Cash-to-Debt is ranked lower than
91% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. DGX: 0.08 )
Ranked among companies with meaningful Cash-to-Debt only.
DGX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.09 Max: N/A
Current: 0.08
Equity-to-Asset 0.46
DGX's Equity-to-Asset is ranked lower than
73% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. DGX: 0.46 )
Ranked among companies with meaningful Equity-to-Asset only.
DGX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.44 Max: 0.62
Current: 0.46
0.3
0.62
Interest Coverage 8.08
DGX's Interest Coverage is ranked lower than
68% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.16 vs. DGX: 8.08 )
Ranked among companies with meaningful Interest Coverage only.
DGX' s Interest Coverage Range Over the Past 10 Years
Min: 5.74  Med: 7.97 Max: 9.27
Current: 8.08
5.74
9.27
Piotroski F-Score: 7
Altman Z-Score: 3.75
Beneish M-Score: -2.66
WACC vs ROIC
7.01%
9.93%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 15.76
DGX's Operating Margin % is ranked higher than
86% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. DGX: 15.76 )
Ranked among companies with meaningful Operating Margin % only.
DGX' s Operating Margin % Range Over the Past 10 Years
Min: 13.22  Med: 16.93 Max: 20.64
Current: 15.76
13.22
20.64
Net Margin % 9.28
DGX's Net Margin % is ranked higher than
78% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. DGX: 9.28 )
Ranked among companies with meaningful Net Margin % only.
DGX' s Net Margin % Range Over the Past 10 Years
Min: 5.07  Med: 8.3 Max: 11.88
Current: 9.28
5.07
11.88
ROE % 15.12
DGX's ROE % is ranked higher than
79% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. DGX: 15.12 )
Ranked among companies with meaningful ROE % only.
DGX' s ROE % Range Over the Past 10 Years
Min: 10.72  Med: 14.94 Max: 20.93
Current: 15.12
10.72
20.93
ROA % 6.95
DGX's ROA % is ranked higher than
77% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.45 vs. DGX: 6.95 )
Ranked among companies with meaningful ROA % only.
DGX' s ROA % Range Over the Past 10 Years
Min: 4.78  Med: 6.64 Max: 9.31
Current: 6.95
4.78
9.31
ROC (Joel Greenblatt) % 105.46
DGX's ROC (Joel Greenblatt) % is ranked higher than
93% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. DGX: 105.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DGX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 88  Med: 116.04 Max: 143.99
Current: 105.46
88
143.99
3-Year Revenue Growth Rate 4.30
DGX's 3-Year Revenue Growth Rate is ranked lower than
58% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. DGX: 4.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DGX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 3.5  Med: 7.9 Max: 15.4
Current: 4.3
3.5
15.4
3-Year EBITDA Growth Rate -2.40
DGX's 3-Year EBITDA Growth Rate is ranked lower than
63% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. DGX: -2.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DGX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -2.4  Med: 9.3 Max: 44.4
Current: -2.4
-2.4
44.4
3-Year EPS without NRI Growth Rate -5.30
DGX's 3-Year EPS without NRI Growth Rate is ranked lower than
57% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. DGX: -5.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DGX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 8.45 Max: 61.5
Current: -5.3
0
61.5
GuruFocus has detected 5 Warning Signs with Quest Diagnostics Inc $DGX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DGX's 30-Y Financials

Financials (Next Earnings Date: 2017-10-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

DGX Guru Trades in Q3 2016

Lee Ainslie 37,510 sh (New)
John Hussman 76,500 sh (+3725.00%)
Joel Greenblatt 308,220 sh (+73.71%)
Paul Tudor Jones 6,000 sh (unchged)
Bernard Horn 61,733 sh (unchged)
Pioneer Investments Sold Out
Jeff Auxier 69,530 sh (-0.61%)
Murray Stahl 7,250 sh (-0.68%)
Charles Brandes 141,534 sh (-3.58%)
David Dreman 12,702 sh (-5.73%)
Scott Black 28,269 sh (-5.77%)
John Rogers 404,984 sh (-10.90%)
Chris Davis 239,896 sh (-92.68%)
» More
Q4 2016

DGX Guru Trades in Q4 2016

Jim Simons 58,900 sh (New)
Manning & Napier Advisors, Inc 7,625 sh (New)
John Hussman 100,000 sh (+30.72%)
Charles Brandes 141,713 sh (+0.13%)
Bernard Horn 61,733 sh (unchged)
Lee Ainslie Sold Out
Paul Tudor Jones Sold Out
Murray Stahl 6,900 sh (-4.83%)
David Dreman 11,851 sh (-6.70%)
John Rogers 371,880 sh (-8.17%)
Chris Davis 203,698 sh (-15.09%)
Jeff Auxier 53,995 sh (-22.34%)
Joel Greenblatt 234,372 sh (-23.96%)
Scott Black 21,059 sh (-25.50%)
» More
Q1 2017

DGX Guru Trades in Q1 2017

Barrow, Hanley, Mewhinney & Strauss 763 sh (New)
Jeremy Grantham 2,700 sh (New)
Caxton Associates 6,700 sh (New)
Jim Simons 503,700 sh (+755.18%)
Manning & Napier Advisors, Inc 7,625 sh (unchged)
Bernard Horn 61,733 sh (unchged)
Scott Black Sold Out
Murray Stahl 6,800 sh (-1.45%)
David Dreman 11,370 sh (-4.06%)
Jeff Auxier 45,845 sh (-15.09%)
Joel Greenblatt 180,978 sh (-22.78%)
John Hussman 75,000 sh (-25.00%)
Chris Davis 129,419 sh (-36.47%)
John Rogers 220,617 sh (-40.68%)
Charles Brandes 78,932 sh (-44.30%)
» More
Q2 2017

DGX Guru Trades in Q2 2017

Steven Cohen 24,500 sh (New)
Jeremy Grantham 2,800 sh (+3.70%)
Chris Davis 132,589 sh (+2.45%)
David Dreman 11,641 sh (+2.38%)
John Hussman 75,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Charles Brandes Sold Out
Barrow, Hanley, Mewhinney & Strauss 761 sh (-0.26%)
Murray Stahl 6,608 sh (-2.82%)
Jeff Auxier 42,645 sh (-6.98%)
Caxton Associates 6,000 sh (-10.45%)
Jim Simons 435,300 sh (-13.58%)
John Rogers 164,157 sh (-25.59%)
Joel Greenblatt 95,902 sh (-47.01%)
» More
» Details

Insider Trades

Latest Guru Trades with DGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Rogers 2017-06-30 Reduce -25.59%0.06%$97.11 - $111.11 $ 106.751%164,157
Chris Davis 2017-06-30 Add 2.45%$97.11 - $111.11 $ 106.751%132,589
Joel Greenblatt 2017-06-30 Reduce -47.01%0.11%$97.11 - $111.11 $ 106.751%95,902
David Dreman 2017-06-30 Add 2.38%0.02%$97.11 - $111.11 $ 106.751%11,641
Barrow, Hanley, Mewhinney & Strauss 2017-06-30 Reduce -0.26%$97.11 - $111.11 $ 106.751%761
Charles Brandes 2017-06-30 Sold Out 0.12%$97.11 - $111.11 $ 106.751%0
John Rogers 2017-03-31 Reduce -40.68%0.16%$90.54 - $99.74 $ 106.7512%220,617
Joel Greenblatt 2017-03-31 Reduce -22.78%0.06%$90.54 - $99.74 $ 106.7512%180,978
Chris Davis 2017-03-31 Reduce -36.47%0.03%$90.54 - $99.74 $ 106.7512%129,419
Charles Brandes 2017-03-31 Reduce -44.30%0.09%$90.54 - $99.74 $ 106.7512%78,932
David Dreman 2017-03-31 Reduce -4.06%0.02%$90.54 - $99.74 $ 106.7512%11,370
Barrow, Hanley, Mewhinney & Strauss 2017-03-31 New Buy$90.54 - $99.74 $ 106.7512%763
John Rogers 2016-12-31 Reduce -8.17%0.03%$79.93 - $92.6 $ 106.7524%371,880
Joel Greenblatt 2016-12-31 Reduce -23.96%0.08%$79.93 - $92.6 $ 106.7524%234,372
Chris Davis 2016-12-31 Reduce -15.09%0.01%$79.93 - $92.6 $ 106.7524%203,698
Charles Brandes 2016-12-31 Add 0.13%$79.93 - $92.6 $ 106.7524%141,713
David Dreman 2016-12-31 Reduce -6.70%0.04%$79.93 - $92.6 $ 106.7524%11,851
John Rogers 2016-09-30 Reduce -10.90%0.05%$80.92 - $86.36 $ 106.7527%404,984
Joel Greenblatt 2016-09-30 Add 73.71%0.14%$80.92 - $86.36 $ 106.7527%308,220
Chris Davis 2016-09-30 Reduce -92.68%1.09%$80.92 - $86.36 $ 106.7527%239,896
Charles Brandes 2016-09-30 Reduce -3.58%0.01%$80.92 - $86.36 $ 106.7527%141,534
David Dreman 2016-09-30 Reduce -5.73%0.04%$80.92 - $86.36 $ 106.7527%12,702
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NAS:IDXX, NYSE:LH, NYSE:A, NYSE:Q, NYSE:PKI, NYSE:BIO, NAS:DXCM, NAS:INCR, NYSE:CRL, NAS:PRAH, NAS:EXAS, NAS:PRXL, NAS:BRKR, NAS:VWR, NYSE:ALR, NAS:NEOG, NAS:MYGN, NAS:FMI, NAS:MEDP, NAS:AXDX » details
Traded in other countries:QDI.Germany,
Headquarter Location:USA
Quest Diagnostics Inc provides diagnostic testing, information, and services, providing insights that enable patients and physicians to make healthcare decisions. It provides diagnostics for insurers and healthcare information technology businesses.

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates about 90% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing at its national network of 2,000 patient service centers. The firm also runs a diagnostic solutions segment which provides clinical trials testing, risk assessment services, and information technology solutions.

Ratios

vs
industry
vs
history
PE Ratio 21.52
DGX's PE Ratio is ranked higher than
71% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.78 vs. DGX: 21.52 )
Ranked among companies with meaningful PE Ratio only.
DGX' s PE Ratio Range Over the Past 10 Years
Min: 9.09  Med: 17.24 Max: 31.26
Current: 21.52
9.09
31.26
Forward PE Ratio 19.19
DGX's Forward PE Ratio is ranked higher than
77% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.92 vs. DGX: 19.19 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 21.52
DGX's PE Ratio without NRI is ranked higher than
72% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 38.46 vs. DGX: 21.52 )
Ranked among companies with meaningful PE Ratio without NRI only.
DGX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.48  Med: 15.53 Max: 22.3
Current: 21.52
9.48
22.3
Price-to-Owner-Earnings 33.88
DGX's Price-to-Owner-Earnings is ranked higher than
54% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.54 vs. DGX: 33.88 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DGX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.27  Med: 26.4 Max: 129.96
Current: 33.88
12.27
129.96
PB Ratio 3.09
DGX's PB Ratio is ranked higher than
58% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. DGX: 3.09 )
Ranked among companies with meaningful PB Ratio only.
DGX' s PB Ratio Range Over the Past 10 Years
Min: 1.85  Med: 2.47 Max: 4.06
Current: 3.09
1.85
4.06
PS Ratio 1.98
DGX's PS Ratio is ranked higher than
70% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. DGX: 1.98 )
Ranked among companies with meaningful PS Ratio only.
DGX' s PS Ratio Range Over the Past 10 Years
Min: 1.03  Med: 1.35 Max: 2.07
Current: 1.98
1.03
2.07
Price-to-Free-Cash-Flow 18.78
DGX's Price-to-Free-Cash-Flow is ranked higher than
67% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.07 vs. DGX: 18.78 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DGX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.23  Med: 13.87 Max: 21.58
Current: 18.78
8.23
21.58
Price-to-Operating-Cash-Flow 13.69
DGX's Price-to-Operating-Cash-Flow is ranked higher than
74% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.14 vs. DGX: 13.69 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DGX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.98  Med: 10.89 Max: 14.18
Current: 13.69
6.98
14.18
EV-to-EBIT 14.26
DGX's EV-to-EBIT is ranked higher than
82% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 14.26 )
Ranked among companies with meaningful EV-to-EBIT only.
DGX' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.9  Med: 10.4 Max: 15.2
Current: 14.26
5.9
15.2
EV-to-EBITDA 11.87
DGX's EV-to-EBITDA is ranked higher than
78% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.58 vs. DGX: 11.87 )
Ranked among companies with meaningful EV-to-EBITDA only.
DGX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5  Med: 8.6 Max: 12.5
Current: 11.87
5
12.5
PEG Ratio 4.13
DGX's PEG Ratio is ranked lower than
65% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.20 vs. DGX: 4.13 )
Ranked among companies with meaningful PEG Ratio only.
DGX' s PEG Ratio Range Over the Past 10 Years
Min: 0.81  Med: 2.12 Max: 6.28
Current: 4.13
0.81
6.28
Shiller PE Ratio 25.56
DGX's Shiller PE Ratio is ranked higher than
74% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 47.44 vs. DGX: 25.56 )
Ranked among companies with meaningful Shiller PE Ratio only.
DGX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.39  Med: 20.24 Max: 38.66
Current: 25.56
14.39
38.66
Current Ratio 1.64
DGX's Current Ratio is ranked lower than
71% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. DGX: 1.64 )
Ranked among companies with meaningful Current Ratio only.
DGX' s Current Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.28 Max: 2.15
Current: 1.64
0.74
2.15
Quick Ratio 1.55
DGX's Quick Ratio is ranked lower than
66% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. DGX: 1.55 )
Ranked among companies with meaningful Quick Ratio only.
DGX' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.2 Max: 2.03
Current: 1.55
0.7
2.03
Days Inventory 6.34
DGX's Days Inventory is ranked higher than
93% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.72 vs. DGX: 6.34 )
Ranked among companies with meaningful Days Inventory only.
DGX' s Days Inventory Range Over the Past 10 Years
Min: 6.34  Med: 7.69 Max: 8.46
Current: 6.34
6.34
8.46
Days Sales Outstanding 45.55
DGX's Days Sales Outstanding is ranked higher than
71% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.84 vs. DGX: 45.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
DGX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.51  Med: 43.71 Max: 48.01
Current: 45.55
40.51
48.01

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.64
DGX's Dividend Yield % is ranked higher than
72% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. DGX: 1.64 )
Ranked among companies with meaningful Dividend Yield % only.
DGX' s Dividend Yield % Range Over the Past 10 Years
Min: 0.62  Med: 0.91 Max: 2.46
Current: 1.64
0.62
2.46
Dividend Payout Ratio 0.35
DGX's Dividend Payout Ratio is ranked higher than
52% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.34 vs. DGX: 0.35 )
Ranked among companies with meaningful Dividend Payout Ratio only.
DGX' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.1  Med: 0.17 Max: 0.45
Current: 0.35
0.1
0.45
3-Year Dividend Growth Rate 10.60
DGX's 3-Year Dividend Growth Rate is ranked higher than
53% of the 34 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. DGX: 10.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
DGX' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3.15 Max: 55.4
Current: 10.6
0
55.4
Forward Dividend Yield % 1.69
DGX's Forward Dividend Yield % is ranked higher than
70% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.11 vs. DGX: 1.69 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 6.93
DGX's 5-Year Yield-on-Cost % is ranked higher than
93% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.46 vs. DGX: 6.93 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
DGX' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.62  Med: 3.84 Max: 10.39
Current: 6.93
2.62
10.39
3-Year Average Share Buyback Ratio 1.60
DGX's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. DGX: 1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DGX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.9  Med: 1.5 Max: 7
Current: 1.6
-16.9
7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.40
DGX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
74% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.25 vs. DGX: 1.40 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DGX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.66  Med: 0.9 Max: 3.77
Current: 1.4
0.66
3.77
Price-to-Intrinsic-Value-DCF (Earnings Based) 2.01
DGX's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
56% of the 18 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.07 vs. DGX: 2.01 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.47
DGX's Price-to-Median-PS-Value is ranked lower than
78% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. DGX: 1.47 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DGX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 1.03 Max: 1.65
Current: 1.47
0.24
1.65
Earnings Yield (Greenblatt) % 7.01
DGX's Earnings Yield (Greenblatt) % is ranked higher than
91% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.04 vs. DGX: 7.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DGX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 6.6  Med: 9.6 Max: 16.9
Current: 7.01
6.6
16.9
Forward Rate of Return (Yacktman) % 7.95
DGX's Forward Rate of Return (Yacktman) % is ranked higher than
52% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.57 vs. DGX: 7.95 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
DGX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.8  Med: 14.3 Max: 25.1
Current: 7.95
7.8
25.1

More Statistics

Revenue (TTM) (Mil) $7,588.00
EPS (TTM) $ 4.96
Beta0.99
Short Percentage of Float4.61%
52-Week Range $79.12 - 112.97
Shares Outstanding (Mil)136.41

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 7,711 7,870 8,060
EPS ($) 5.59 6.03 6.39
EPS without NRI ($) 5.59 6.03 6.39
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.03%
Dividends per Share ($) 1.79 1.98 2.15
» More Articles for DGX

Headlines

Articles On GuruFocus.com
Mountainside Fitness Partners with Sonora Quest Laboratories to Offer Customized Wellness Testing to Aug 01 2017 
Quest Diagnostics Launches QHerit™, a Pan-Ethnic Genetic Screening Panel Aligned with New Medical Jul 19 2017 
Quest Diagnostics Completes Acquisition of Med Fusion and Clear Point in Texas, Forming National Pre Jul 18 2017 
Quest Diagnostics Adds Custom Coaching, At-Home Collection to Expand Blueprint for Athletes™ Servi Jun 22 2017 
Quest Diagnostics to Form Precision Oncology Center of Excellence Through Acquisition of Two Texas L Jun 12 2017 
Data Diagnostics Wins 2017 MedTech Breakthrough Award Jun 08 2017 
New Study: Physicians Lack the Right Tools to Close Costly Gaps in Healthcare Jun 06 2017 
Quest Diagnostics Declares Quarterly Cash Dividend May 16 2017 
Increases in Illicit Drugs, Including Cocaine, Drive Workforce Drug Positivity to Highest Rate in 12 May 16 2017 
Quest Diagnostics To Speak At The UBS Global Healthcare Conference May 12 2017 

More From Other Websites
Edited Transcript of DGX earnings conference call or presentation 25-Jul-17 12:30pm GMT Aug 13 2017
See what the IHS Markit Score report has to say about Quest Diagnostics Inc. Aug 12 2017
Mountainside Fitness Partners with Sonora Quest Laboratories to Offer Customized Wellness Testing to... Aug 01 2017
Quest Diagnostics, Inc. :DGX-US: Earnings Analysis: Q2, 2017 By the Numbers : July 27, 2017 Jul 27 2017
Amedisys (AMED) Earnings & Revenues Miss Estimates in Q2 Jul 27 2017
Edwards Lifesciences (EW) Tops Q2 Earnings & Sales, View Up Jul 27 2017
Thermo Fisher (TMO) Tops Q2 Earnings & Revenues, View Up Jul 26 2017
Quest Diagnostics, Inc. breached its 50 day moving average in a Bearish Manner : DGX-US : July 26,... Jul 26 2017
Quest Diagnostics tops 2Q profit forecasts Jul 25 2017
Quest Diagnostics (DGX) Tops Q2 Earnings, Raises '17 View Jul 25 2017
Quest Diagnostics Reports Second Quarter 2017 Financial Results, Raises 2017 Financial Outlook Jul 25 2017
Investor Network: Quest Diagnostics Incorporated to Host Earnings Call Jul 25 2017
Healthcare Q2 Earnings Slated on Jul 25: HCA, UHS & More Jul 24 2017
Quest Diagnostics Closes Deal to Acquire 2 Labs in Texas Jul 20 2017
Can Quest Diagnostics (DGX) Pull a Surprise in Q2 Earnings? Jul 18 2017
Quest Diagnostics Completes Acquisition of Med Fusion and Clear Point in Texas, Forming National... Jul 18 2017
5 of the Best US Stock Picks for a Patriotic (and Profitable) Summer Jul 17 2017
3 Excellent Value Picks Amid Political Grind in MedTech Jul 11 2017
Quest Diagnostics To Release Second Quarter 2017 Financial Results On July 25 Jul 06 2017
Dividend Coverage: Quest Diagnostics has a Dividend Yield of 1.63%; Will Trade Ex-Dividend on July... Jul 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)